The long-term antiproteinuric effect of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney disease

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 13, Issue 1, 2012, Pages 113-117

  Tsuboi, Nobuo ^a   Kawamura, Tetsuya ^a   Okonogi, Hideo ^a   Ishii, Takeo ^a   Hosoya, Tatsuo ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic kidney disease; eplerenone; proteinuria; renal function; renin angiotensin aldosterone system

Indexed keywords

CREATININE; EPLERENONE; POTASSIUM;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CREATININE CLEARANCE; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; LONG TERM CARE; MALE; MEAN ARTERIAL PRESSURE; POTASSIUM BLOOD LEVEL; PROTEIN URINE LEVEL; PROTEINURIA; TREATMENT DURATION; URINARY EXCRETION;

ADULT; AGED; ALDOSTERONE ANTAGONISTS; BLOOD PRESSURE; DIABETIC NEPHROPATHIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROTEINURIA; SPIRONOLACTONE; TIME FACTORS;

EID: 84859998982     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320311412811     Document Type: Article

References (13)

1. Remuzzi G, Benigi A and Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006; 116: 288-296. (Pubitemid 43228342)
2. Catapano F, Chiodini P, De Nicola L, et al. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. Am J Kidney Dis 2008; 52: 475-485.
3. Parving HH, Person F, Lewis JB, et al. AVOID Study investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433-2446. (Pubitemid 351793017)
4. Epstein M. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med 2006; 119: 912-919. (Pubitemid 44634312)
5. Nagase M, Yoshida S, Shibata S, et al. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol 2006; 17: 3438-3446. (Pubitemid 44865286)
6. Bomback AS, Kshirsagar AV, Amamoo A, et al. Change in proteinuria after adding aldosterone blocker to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 2008; 51: 199-211.
7. Bianchi S, Bigazzi R, Campese VM, et al. Antagonist of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis 2005; 46: 45-51. (Pubitemid 40848432)
8. Sato A, Hayashi K and Saruta T. Antiproteinuric effects of mineralcorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005; 18: 44-49. (Pubitemid 40187348)
9. Chrysostomou A, Pedagogos E, MacGregor L, et al. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 2006; 1: 256-262.
10. Tylicki L, Rutkowski P, Renke M, et al. Triple blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis 2008; 52: 486-493.
11. Matsuo S, Imai E, Horio M, et al.; Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992.
12. Epstein M, Williams GH, Weinberger M, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006; 1: 940-951.
13. Ando K, Ohtsu H, Arakawa Y, et al. Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect Study Investigators. Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria. Hypertens Res 2010; 33: 616-621.